{"name":"Nicole Fram M.D.","slug":"nicole-fram-m-d","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Prolensa 0.07% Ophthalmic Solution","genericName":"Prolensa 0.07% Ophthalmic Solution","slug":"prolensa-0-07-ophthalmic-solution","indication":"Postoperative inflammation and pain following cataract surgery","status":"marketed"}]}],"pipeline":[{"name":"Prolensa 0.07% Ophthalmic Solution","genericName":"Prolensa 0.07% Ophthalmic Solution","slug":"prolensa-0-07-ophthalmic-solution","phase":"marketed","mechanism":"Prolensa is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce inflammation and pain in the eye.","indications":["Postoperative inflammation and pain following cataract surgery","Ocular itching associated with allergic conjunctivitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxON3VpTkxvUEtHM2U2WnlxU0NMSDNiR24xQkZpNXVjQjNKREdSaWZtVkhHUjJsbFdqbXlPc0dmeUduVVJWUkU2V2VxbTROZDhSZUhBeWp1U3RYUlV0VExhdEFmMzBQOU5jUFpMdWVmVFoyUmhOOXdKMFlyMmY2VG1YTzJtWUM4QUF2a3lzcC1jTGprbFpERXN0ckV1RXppRVh4ZEd0LVZGWmhyRkF5N2ZB?oc=5","date":"2026-01-20","type":"pipeline","source":"Eyes On Eyecare","summary":"Leadership watch: OKYO, Orbis, and BVI Medical name new CEOs - Eyes On Eyecare","headline":"Leadership watch: OKYO, Orbis, and BVI Medical name new CEOs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNNmMxUU9hY2lWcFQ3WERYdXlhZmJ6ZGI4eXZwcmd6b0xfMjJVeFY1MlpscGowaTZtU2thY2c5X1lkb2tHc2tsUVZKZnVtczhKQndGX3VHMmxtczZUNmVqLW11eXRhdHEtSzNqaW8xcDZKTHdNMUFzd1R3TUJXT0U1c3dvWk0xLUFBLU91dlBUVlV0dUlzZUxr?oc=5","date":"2025-04-24","type":"pipeline","source":"Eyes On Eyecare","summary":"BVI Medical and Neurotech name new CCOs - Eyes On Eyecare","headline":"BVI Medical and Neurotech name new CCOs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQYWtuOVhkY2ZNQl9rOFp5UFNMZk5BUngteXVUbVpmZ1ZtdTRBN3lJMVpwUWQ3UTRhODdFTXRObDF0QVdMMGJGU2M4WmZWSEpDZWlnaDVNX1RvQjRkRE1wbFctTjVpckpiSkZ2R2lHZ0JHSUp5YkRHZS1WbmcyS19NVlljYWxfUml5dTd1akhVd0tZUDQ?oc=5","date":"2024-09-23","type":"regulatory","source":"EyeWorld","summary":"On- and off-label indications for small aperture technology - EyeWorld","headline":"On- and off-label indications for small aperture technology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFA0dUgxQTFGb1RJYnliZlRHWUd4TU1DZzhORzQxUnVOd0VOLW5Xcy1MUFlta2xITTJ0SjNyZDBLZE9jdkhpRUVibUYxNGcwLWV0YlRsbE9BSmZISXV0dDJOWklVWnZuT2tpeWc?oc=5","date":"2022-05-27","type":"pipeline","source":"EyeWorld","summary":"EyeWorld Weekly, May 27, 2022 - EyeWorld","headline":"EyeWorld Weekly, May 27, 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQRmpkdldpdHR5X3FQdkQ5NHJCRUdrWUI5cUdhUThuSEFMS09OVWtJSVBqT3BBY2JaVjFiTy1IYmVkdnptMmpsOHNDRHBvSVVHWWlBSjFwRGtuNzVnTkwzak9oWVlUZGhxRmJXaWNhcXBVelRSUXRlQXJzY0RkRVVmb3RR?oc=5","date":"2022-05-13","type":"pipeline","source":"EyeWorld","summary":"Rapid-fire presentations featured in ‘X-Rounds’ - EyeWorld","headline":"Rapid-fire presentations featured in ‘X-Rounds’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQTjQ4WVU2MHBJdGRTZ2NHeFNqdTZwVG9sNjhuNlM0cXFfLUVXWlQ1akhLa0lOVzBOckxOLXNtbW12c3JuUXBQN0ttWHY2QVg2Slc4amVVTC1KMUcwUE1BcC0yM0d6NnM5TXNnQWJHOThXa1Q2S0NsR0RVRW10NDNUNFQ5WU5ZaUR3NkVVd0NvTWt4X0JUWEJJbmhwd24?oc=5","date":"2022-01-27","type":"pipeline","source":"EyeWorld","summary":"Negative dysphotopsia: How to explain it and management strategies - EyeWorld","headline":"Negative dysphotopsia: How to explain it and management strategies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNWlAtVE1yaS1zZ2ZaeVFmQTVzN0JIVmxqeUowUUZxdXIwZEc5WWx4TGRuUkVIQ1BFNmFnSlhKWGFvTWUybXdYdnlvTjZtOTFHZzJ6SnF1NV9wQXQxUU1DaGhLVzVVaGNXVEhWREV0VWIzLVBWSWNnb2JTUXZ5VFlHWmhNdlZCc09PdURDOVNvenpRUXdDNTA5TUVjTkxxelZtY2xJQ2JsVjhWc0xlWC0yc2E2VmU1eHM4cnkzTFp3?oc=5","date":"2021-09-22","type":"pipeline","source":"Healio","summary":"Treatment landscape for presbyopia evolving toward noninvasive options - Healio","headline":"Treatment landscape for presbyopia evolving toward noninvasive options","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}